LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV)BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Dat ...
BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Data show stable disease as best clinical response with no notable adverse events ...
TMB and various biomarkers were positively associated with improved pCR and EFS in high-risk, early-stage TNBC, regardless of ...
The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...
James “Jimmy” Carter, the 39th President of the United States, passed away last week on December 29, after 22 months in Hospice care. At | Cancer ...
Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...
The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...
The European Society for Medical Oncology (ESMO) Congress featured findings on overall survival, disparities, and artificial ...
What remains after the passing of former President Jimmy Carter encompasses more than politics and humanitarianism, it also includes cancer care, according to a Dec. 29 NBC News report.
Medpage Today on MSN9d
Using Immune Biomarkers to Guide Treatment in TNBCHigh levels of immune infiltrates are strongly prognostic for favorable outcomes independently of nodal status in ...
Lenvatinib plus pembrolizumab did not improve PFS or OS over chemotherapy in patients with advanced or recurrent endometrial ...
He also revealed that he would be treated with a relatively new immunotherapy called pembrolizumab, sold as Keytruda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback